Medication info

Olmesartan Medoxomil/ Rosuvastatin 20/10 mg

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Korea Prime Pharm Co., Ltd.
Appearance
White or pale yellow round film-coated tablets
Packaging
30 tablets/box [30 tablets (10 tablets/Alu-Alu) X 3]
Approval status
Approval withdrawn

MFDS item code 202003983 · Approved 2020.05.28

This product's status changed to Approval withdrawn on 2024.09.19. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension and dyslipidemia, suppression of atherosclerotic progression and cardiovascular disease risk
Who takes it
Adults · Children
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each of the active ingredients, olmesartan medoxomil and rosuvastatin. Olmesartan medoxomil The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg daily. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a lower dose while closely monitoring their condition. No dose adjustment is necessary when this medicine is administered to patients aged 65 years or older. The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. No dose adjustment is necessary in patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, which may be increased to a maximum of 20mg daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. Rosuvastatin Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia: Patients should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams daily. Elderly patients: No dose adjustment is necessary. No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Special caution is required when administering 20mg of this medicine to patients with moderate renal impairment. Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose is contraindicated in some of these patients. For patients taking olmesartan medoxomil and rosuvastatin concomitantly, they may be switched to this medicine (a fixed-dose combination with the same amount of each active ingredient) for convenience.
Child dose
Safety and efficacy have not been established in children under 18 years of age.

Ingredients

Manufacturer
Korea Prime Pharm Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia, suppression of atherosclerotic progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • coronary heart disease
  • elevated hypersensitive C-reactive protein
  • hypertension
  • low HDL cholesterol
  • smoking
View approved original text

This medication is prescribed for patients who need to take both ingredients, olmesartan medoxomil and rosuvastatin. Olmesartan medoxomil is primarily used to treat essential hypertension. Rosuvastatin helps with primary hypercholesterolemia and mixed hyperlipidemia that are not controlled by diet and exercise, and it is also used as an adjunctive treatment for familial homozygous hypercholesterolemia and primary dysbetalipoproteinemia. Additionally, it lowers cholesterol levels in patients with hypercholesterolemia, delaying the progression of atherosclerosis and effectively reducing the risk of stroke, myocardial infarction, and revascularization procedures in patients at high risk of cardiovascular diseases. The combination of these two medications simultaneously improves blood pressure and blood lipid management, effectively protecting the cardiovascular health of patients.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each of the active ingredients, olmesartan medoxomil and rosuvastatin. Olmesartan medoxomil The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg daily. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a lower dose while closely monitoring their condition. No dose adjustment is necessary when this medicine is administered to patients aged 65 years or older. The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. No dose adjustment is necessary in patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, which may be increased to a maximum of 20mg daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. Rosuvastatin Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia: Patients should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams daily. Elderly patients: No dose adjustment is necessary. No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Special caution is required when administering 20mg of this medicine to patients with moderate renal impairment. Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose is contraindicated in some of these patients. For patients taking olmesartan medoxomil and rosuvastatin concomitantly, they may be switched to this medicine (a fixed-dose combination with the same amount of each active ingredient) for convenience.

Child dose

Safety and efficacy have not been established in children under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and neonate if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Individuals with allergies to this medication or its components, pregnant or potentially pregnant women, and lactating women should not take it. Patients with significantly impaired renal function, those undergoing kidney dialysis, severe liver dysfunction, or biliary obstruction should not use this medication. Patients with a history of muscle disorders or those at high risk of muscle problems must consult their doctor before taking this medication, and should avoid high-dose administration. This medication contains lactose, so patients with certain genetic lactose intolerance should not take it. Patients with low blood pressure or low salt levels may experience hypotensive symptoms at the beginning of treatment, so they should be monitored closely. Patients with weakened renal function or those who have had a kidney transplant should have their renal function and electrolyte levels monitored regularly through blood tests. Due to the risk of hyperkalemia, potassium levels should be checked periodically, and patients with heart or blood pressure-related conditions require special attention. This medication may cause muscle pain, muscle weakness, and rarely severe muscle damage known as rhabdomyolysis; if symptoms of muscle pain or weakness occur, notify medical personnel immediately. Liver function abnormalities may occur, so liver function tests should be performed regularly before and during treatment with this medication. Dizziness or drowsiness may occur, so caution is needed when driving or operating hazardous machinery. This medication may interact with other drugs, so inform your doctor or pharmacist if you are taking other medications. Pregnant or nursing women should not take this medication, and women who may become pregnant should use appropriate contraceptive methods. Safety for use in children or adolescents under 18 has not been established. Elderly patients may have higher blood concentrations of this medication, so dose adjustment and caution are necessary. In case of overdose, hypotension or cardiac irregularities may occur, requiring immediate medical attention and appropriate treatment if necessary. This medication should be kept out of reach of children and should not be transferred to another container.

Side effects

ALT elevation, AST elevation, increased blood creatinine, decreased creatinine clearance, headache, dizziness, decreased sensation, neuromyopathy, drowsiness, gastroesophageal reflux disease, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest discomfort, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial swelling, muscle weakness, angioedema, anaphylactic reaction, vomiting, chronic malabsorption syndrome, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, itchiness, hives, autoimmune hepatitis, dizziness (including positional vertigo), palpitations, increased blood pressure, elevated blood creatinine, cough, nasal bleeding, upper respiratory infection, asthma, hypersensitivity reactions including angioedema, diabetes, constipation, nausea, abdominal pain, pancreatitis, itchiness, rash, hives, myalgia, myopathy, rhabdomyolysis, muscle weakness, polyneuropathy, memory loss, peripheral neuropathy, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to protect it from air and moisture, and the storage temperature should be maintained at room temperature between 1 to 30 degrees Celsius. This will safely maintain the medication's efficacy.

Appearance and packaging

Appearance

White or pale yellow round film-coated tablets

Package unit

30 tablets/box [30 tablets (10 tablets/Alu-Alu) X 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.